|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:BICC1-FGFR2 (FusionGDB2 ID:9736) |
Fusion Gene Summary for BICC1-FGFR2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: BICC1-FGFR2 | Fusion gene ID: 9736 | Hgene | Tgene | Gene symbol | BICC1 | FGFR2 | Gene ID | 80114 | 2263 |
Gene name | BicC family RNA binding protein 1 | fibroblast growth factor receptor 2 | |
Synonyms | BICC|CYSRD | BBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25 | |
Cytomap | 10q21.1 | 10q26.13 | |
Type of gene | protein-coding | protein-coding | |
Description | protein bicaudal C homolog 1FGFR2-BICC1 fusion kinase proteinbicaudal C homolog 1 | fibroblast growth factor receptor 2BEK fibroblast growth factor receptorbacteria-expressed kinasekeratinocyte growth factor receptorprotein tyrosine kinase, receptor like 14 | |
Modification date | 20200313 | 20200322 | |
UniProtAcc | . | P21802 | |
Ensembl transtripts involved in fusion gene | ENST00000373886, ENST00000263103, ENST00000476684, | ENST00000369061, ENST00000357555, ENST00000358487, ENST00000356226, ENST00000369060, ENST00000369059, ENST00000346997, ENST00000457416, ENST00000351936, ENST00000360144, ENST00000369056, ENST00000490349, ENST00000359354, ENST00000478859, | |
Fusion gene scores | * DoF score | 10 X 9 X 6=540 | 11 X 11 X 8=968 |
# samples | 9 | 16 | |
** MAII score | log2(9/540*10)=-2.58496250072116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(16/968*10)=-2.59693514238723 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: BICC1 [Title/Abstract] AND FGFR2 [Title/Abstract] AND fusion [Title/Abstract] Identification of Targetable FGFR Gene Fusions in Diverse Cancers (pmid: 23558953) | ||
Most frequent breakpoint | FGFR2(123243212)-BICC1(60461834), # samples:6 BICC1(60563002)-FGFR2(123239535), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | FGFR2-BICC1 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. FGFR2-BICC1 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. FGFR2-BICC1 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. FGFR2-BICC1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | BICC1 | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 21922595 |
Tgene | FGFR2 | GO:0008284 | positive regulation of cell proliferation | 8663044 |
Tgene | FGFR2 | GO:0008543 | fibroblast growth factor receptor signaling pathway | 8663044|15629145 |
Tgene | FGFR2 | GO:0018108 | peptidyl-tyrosine phosphorylation | 15629145|16844695 |
Tgene | FGFR2 | GO:0046777 | protein autophosphorylation | 15629145 |
Fusion gene breakpoints across BICC1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across FGFR2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | CHOL | TCGA-W5-AA2W-01A | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
ChimerDB4 | CHOL | TCGA-W5-AA2W-01A | BICC1 | chr10 | 60563002 | - | FGFR2 | chr10 | 123239535 | - |
Top |
Fusion Gene ORF analysis for BICC1-FGFR2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000373886 | ENST00000369061 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000357555 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000358487 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000356226 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000369060 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000369059 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000346997 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000457416 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000351936 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000360144 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000369056 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000490349 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000359354 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000373886 | ENST00000478859 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
In-frame | ENST00000263103 | ENST00000369061 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000357555 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000358487 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000356226 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000369060 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000369059 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000346997 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000457416 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000351936 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000360144 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000369056 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000490349 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000359354 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
5CDS-intron | ENST00000263103 | ENST00000478859 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-3CDS | ENST00000476684 | ENST00000369061 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000357555 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000358487 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000356226 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000369060 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000369059 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000346997 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000457416 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000351936 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000360144 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000369056 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000490349 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000359354 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
intron-intron | ENST00000476684 | ENST00000478859 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000373886 | BICC1 | chr10 | 60563002 | + | ENST00000369061 | FGFR2 | chr10 | 123239535 | - | 3873 | 2185 | 4 | 2349 | 781 |
ENST00000263103 | BICC1 | chr10 | 60563002 | + | ENST00000369061 | FGFR2 | chr10 | 123239535 | - | 2771 | 1083 | 21 | 1247 | 408 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000373886 | ENST00000369061 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - | 0.000624666 | 0.9993754 |
ENST00000263103 | ENST00000369061 | BICC1 | chr10 | 60563002 | + | FGFR2 | chr10 | 123239535 | - | 0.001588256 | 0.9984118 |
Top |
Fusion Genomic Features for BICC1-FGFR2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for BICC1-FGFR2 |
Go to FGviewer for the breakpoints of chr10:60563002-chr10:123239535 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | FGFR2 |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | BICC1 | chr10:60563002 | chr10:123239535 | ENST00000373886 | + | 15 | 21 | 132_199 | 727.0 | 975.0 | Domain | KH 1 |
Hgene | BICC1 | chr10:60563002 | chr10:123239535 | ENST00000373886 | + | 15 | 21 | 284_348 | 727.0 | 975.0 | Domain | KH 2 |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 154_247 | 0 | 786.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 256_358 | 0 | 786.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 25_125 | 0 | 786.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 481_770 | 0 | 786.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 154_247 | 0 | 708.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 256_358 | 0 | 708.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 25_125 | 0 | 708.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 481_770 | 0 | 708.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 154_247 | 0 | 255.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 256_358 | 0 | 255.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 25_125 | 0 | 255.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 481_770 | 0 | 255.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 154_247 | 0 | 681.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 256_358 | 0 | 681.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 25_125 | 0 | 681.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 481_770 | 0 | 681.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 154_247 | 0 | 770.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 256_358 | 0 | 770.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 25_125 | 0 | 770.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 481_770 | 0 | 770.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 487_495 | 0 | 786.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 565_567 | 0 | 786.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 487_495 | 0 | 708.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 565_567 | 0 | 708.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 487_495 | 0 | 255.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 565_567 | 0 | 255.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 487_495 | 0 | 681.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 565_567 | 0 | 681.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 487_495 | 0 | 770.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 565_567 | 0 | 770.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 161_178 | 0 | 786.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 161_178 | 0 | 708.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 161_178 | 0 | 255.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 161_178 | 0 | 681.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 161_178 | 0 | 770.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 22_377 | 0 | 786.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 399_821 | 0 | 786.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 22_377 | 0 | 708.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 399_821 | 0 | 708.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 22_377 | 0 | 255.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 399_821 | 0 | 255.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 22_377 | 0 | 681.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 399_821 | 0 | 681.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 22_377 | 0 | 770.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 399_821 | 0 | 770.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000351936 | 0 | 18 | 378_398 | 0 | 786.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000357555 | 0 | 17 | 378_398 | 0 | 708.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000359354 | 0 | 7 | 378_398 | 0 | 255.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000360144 | 0 | 17 | 378_398 | 0 | 681.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369056 | 0 | 17 | 378_398 | 0 | 770.0 | Transmembrane | Helical |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | BICC1 | chr10:60563002 | chr10:123239535 | ENST00000373886 | + | 15 | 21 | 873_936 | 727.0 | 975.0 | Domain | SAM |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 154_247 | 765.0 | 820.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 256_358 | 765.0 | 820.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 25_125 | 765.0 | 820.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 481_770 | 765.0 | 820.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 154_247 | 650.0 | 705.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 256_358 | 650.0 | 705.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 25_125 | 650.0 | 705.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 481_770 | 650.0 | 705.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 154_247 | 767.0 | 822.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 256_358 | 767.0 | 822.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 25_125 | 767.0 | 822.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 481_770 | 767.0 | 822.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 154_247 | 651.0 | 706.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 256_358 | 651.0 | 706.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 25_125 | 651.0 | 706.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 481_770 | 651.0 | 706.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 154_247 | 655.0 | 710.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 256_358 | 655.0 | 710.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 25_125 | 655.0 | 710.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 481_770 | 655.0 | 710.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 154_247 | 768.0 | 823.0 | Domain | Note=Ig-like C2-type 2 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 256_358 | 768.0 | 823.0 | Domain | Note=Ig-like C2-type 3 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 25_125 | 768.0 | 823.0 | Domain | Note=Ig-like C2-type 1 | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 481_770 | 768.0 | 823.0 | Domain | Protein kinase | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 487_495 | 765.0 | 820.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 565_567 | 765.0 | 820.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 487_495 | 650.0 | 705.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 565_567 | 650.0 | 705.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 487_495 | 767.0 | 822.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 565_567 | 767.0 | 822.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 487_495 | 651.0 | 706.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 565_567 | 651.0 | 706.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 487_495 | 655.0 | 710.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 565_567 | 655.0 | 710.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 487_495 | 768.0 | 823.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 565_567 | 768.0 | 823.0 | Nucleotide binding | ATP | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 161_178 | 765.0 | 820.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 161_178 | 650.0 | 705.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 161_178 | 767.0 | 822.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 161_178 | 651.0 | 706.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 161_178 | 655.0 | 710.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 161_178 | 768.0 | 823.0 | Region | Note=Heparin-binding | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 22_377 | 765.0 | 820.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 399_821 | 765.0 | 820.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 22_377 | 650.0 | 705.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 399_821 | 650.0 | 705.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 22_377 | 767.0 | 822.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 399_821 | 767.0 | 822.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 22_377 | 651.0 | 706.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 399_821 | 651.0 | 706.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 22_377 | 655.0 | 710.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 399_821 | 655.0 | 710.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 22_377 | 768.0 | 823.0 | Topological domain | Extracellular | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 399_821 | 768.0 | 823.0 | Topological domain | Cytoplasmic | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000346997 | 15 | 17 | 378_398 | 765.0 | 820.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000356226 | 14 | 16 | 378_398 | 650.0 | 705.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000358487 | 16 | 18 | 378_398 | 767.0 | 822.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369060 | 14 | 16 | 378_398 | 651.0 | 706.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000369061 | 13 | 15 | 378_398 | 655.0 | 710.0 | Transmembrane | Helical | |
Tgene | FGFR2 | chr10:60563002 | chr10:123239535 | ENST00000457416 | 16 | 18 | 378_398 | 768.0 | 823.0 | Transmembrane | Helical |
Top |
Fusion Gene Sequence for BICC1-FGFR2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000373886_ENST00000369061_TCGA-W5-AA2W-01A_BICC1_chr10_60563002_+_FGFR2_chr10_123239535_length(transcript)=3873nt_BP=2185nt CACCATGGCCGCCCAGGGAGAGCCCGGCTACCTGGCGGCGCAGTCGGACCCCGGCTCCAACAGCGAGCGCAGCACCGACTCCCCAGTGCC CGGCTCCGAGGACGACTTGGTCGCCGGGGCGACCCTGCACAGCCCGGAGTGGAGCGAGGAGCGCTTCCGCGTGGACAGGAAGAAACTTGA GGCCATGTTACAAGCTGCTGCTGAAGGGAAAGGCAGAAGTGGGGAAGACTTTTTTCAAAAGATCATGGAGGAAACAAATACGCAGATTGC TTGGCCATCAAAACTGAAGATCGGAGCCAAATCCAAGAAAGATCCCCATATTAAGGTTTCTGGAAAGAAAGAAGATGTTAAAGAAGCCAA GGAAATGATCATGTCTGTCTTAGACACAAAAAGCAATCGAGTCACACTGAAGATGGATGTTTCACATACAGAACATTCACATGTAATCGG CAAAGGTGGCAACAATATTAAAAAAGTGATGGAAGAAACCGGATGCCATATCCACTTTCCAGATTCCAACAGGAATAACCAAGCAGAAAA AAGCAACCAGGTATCTATAGCGGGACAACCAGCAGGAGTAGAATCTGCCCGAGTTAGAATTCGGGAGCTGCTTCCTTTGGTGCTGATGTT TGAGCTACCAATTGCTGGAATTCTTCAACCGGTTCCTGATCCTAATTCCCCCTCTATTCAGCATATATCACAAACGTACAATATTTCAGT ATCATTTAAACAGCGTTCCCGAATGTATGGTGCTACTGTCATAGTACGAGGGTCTCAGAATAACACTAGTGCTGTGAAGGAAGGAACTGC CATGCTGTTAGAACATCTTGCTGGGAGCTTAGCATCAGCTATTCCTGTGAGCACACAACTAGATATTGCAGCTCAACATCATCTCTTTAT GATGGGTCGAAATGGGAGCAACATCAAACATATCATGCAGAGAACAGGTGCTCAGATCCACTTTCCTGATCCCAGTAATCCACAAAAGAA ATCTACCGTCTACCTCCAGGGCACCATTGAGTCTGTCTGTCTTGCAAGGCAATATCTCATGGGTTGTCTTCCTCTTGTGTTGATGTTTGA TATGAAGGAAGAAATTGAAGTAGATCCACAATTCATTGCGCAGTTGATGGAACAGCTTGATGTCTTCATCAGTATTAAACCAAAGCCCAA ACAGCCAAGCAAGTCTGTGATTGTGAAAAGTGTTGAGCGAAATGCCTTAAATATGTATGAAGCAAGGAAATGTCTCCTCGGACTTGAAAG CAGTGGGGTTACCATAGCAACCAGTCCATCCCCAGCATCCTGCCCTGCCGGCCTGGCATGTCCCAGCCTGGATATCTTAGCTTCAGCAGG CCTTGGACTCACTGGACTAGGTCTTTTGGGACCCACCACCTTATCTCTGAACACTTCAACAACCCCAAACTCACTCTTGAATGCTCTTAA TAGCTCAGTCAGTCCTTTGCAAAGTCCAAGTTCTGGTACACCCAGCCCCACATTATGGGCACCCCCACTTGCTAATACTTCAAGTGCCAC AGGTTTTTCTGCTATACCACACCTTATGATTCCATCTACTGCCCAAGCCACATTAACTAATATTTTGTTGTCTGGAGTGCCCACCTATGG GCACACAGCTCCATCTCCCCCTCCTGGCTTGACTCCTGTTGATGTCCATATCAACAGTATGCAGACCGAAGGCAAAAAAATCTCTGCTGC TTTAAATGGACATGCACAGTCTCCAGATATAAAATATGGTGCAATATCCACTTCATCACTTGGAGAAAAAGTGCTGAGTGCAAATCACGG GGATCCGTCCATCCAGACAAGTGGGTCTGAGCAGACATCTCCCAAATCAAGCCCCACTGAAGGTTGTAATGATGCTTTTGTTGAAGTAGG CATGCCTCGAAGTCCTTCCCATTCTGGGAATGCTGGTGACTTGAAACAGATGATGTGTCCCTCCAAGGTTTCCTGTGCCAAAAGGCAGAC AGTGGAACTATTGCAAGGCACGAAAAACTCACACTTACACAGCACTGACAGGTTGCTCTCAGACCCTGAACTGAGTGCTACCGAAAGCCC TTTGGCTGACAAGAAGGCTCCAGGGAGTGAGCGCGCTGCAGAGAGGGCAGCAGCTGCCCAGCAAAACTCCGAAAGGGCCCACCTTGCTCC ACGGTCATCATATGTCAACATGCAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCACCTAGTTACCCTGACACAAGAAGTTC TTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCAGACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGT TAAAACATGAATGACTGTGTCTGCCTGTCCCCAAACAGGACAGCACTGGGAACCTAGCTACACTGAGCAGGGAGACCATGCCTCCCAGAG CTTGTTGTCTCCACTTGTATATATGGATCAGAGGAGTAAATAATTGGAAAAGTAATCAGCATATGTGTAAAGATTTATACAGTTGAAAAC TTGTAATCTTCCCCAGGAGGAGAAGAAGGTTTCTGGAGCAGTGGACTGCCACAAGCCACCATGTAACCCCTCTCACCTGCCGTGCGTACT GGCTGTGGACCAGTAGGACTCAAGGTGGACGTGCGTTCTGCCTTCCTTGTTAATTTTGTAATAATTGGAGAAGATTTATGTCAGCACACA CTTACAGAGCACAAATGCAGTATATAGGTGCTGGATGTATGTAAATATATTCAAATTATGTATAAATATATATTATATATTTACAAGGAG TTATTTTTTGTATTGATTTTAAATGGATGTCCCAATGCACCTAGAAAATTGGTCTCTCTTTTTTTAATAGCTATTTGCTAAATGCTGTTC TTACACATAATTTCTTAATTTTCACCGAGCAGAGGTGGAAAAATACTTTTGCTTTCAGGGAAAATGGTATAACGTTAATTTATTAATAAA TTGGTAATATACAAAACAATTAATCATTTATAGTTTTTTTTGTAATTTAAGTGGCATTTCTATGCAGGCAGCACAGCAGACTAGTTAATC TATTGCTTGGACTTAACTAGTTATCAGATCCTTTGAAAAGAGAATATTTACAATATATGACTAATTTGGGGAAAATGAAGTTTTGATTTA TTTGTGTTTAAATGCTGCTGTCAGACGATTGTTCTTAGACCTCCTAAATGCCCCATATTAAAAGAACTCATTCATAGGAAGGTGTTTCAT TTTGGTGTGCAACCCTGTCATTACGTCAACGCAACGTCTAACTGGACTTCCCAAGATAAATGGTACCAGCGTCCTCTTAAAAGATGCCTT AATCCATTCCTTGAGGACAGACCTTAGTTGAAATGATAGCAGAATGTGCTTCTCTCTGGCAGCTGGCCTTCTGCTTCTGAGTTGCACATT AATCAGATTAGCCTGTATTCTCTTCAGTGAATTTTGATAATGGCTTCCAGACTCTTTGGCGTTGGAGACGCCTGTTAGGATCTTCAAGTC CCATCATAGAAAATTGAAACACAGAGTTGTTCTGCTGATAGTTTTGGGGATACGTCCATCTTTTTAAGGGATTGCTTTCATCTAATTCTG GCAGGACCTCACCAAAAGATCCAGCCTCATACCTACATCAGACAAAATATCGCCGTTGTTCCTTCTGTACTAAAGTATTGTGTTTTGCTT TGGAAACACCCACTCACTTTGCAATAGCCGTGCAAGATGAATGCAGATTACACTGATCTTATGTGTTACAAAATTGGAGAAAGTATTTAA TAAAACCTGTTAATTTTTATACTGACAATAAAAATGTTTCTACAGATATTAATGTTAACAAGACAAAATAAATGTCACGCAACTTATTTT >In-frame_ENST00000373886_ENST00000369061_TCGA-W5-AA2W-01A_BICC1_chr10_60563002_+_FGFR2_chr10_123239535_length(amino acids)=781AA_start in transcript=4_stop in transcript=2349 MAAQGEPGYLAAQSDPGSNSERSTDSPVPGSEDDLVAGATLHSPEWSEERFRVDRKKLEAMLQAAAEGKGRSGEDFFQKIMEETNTQIAW PSKLKIGAKSKKDPHIKVSGKKEDVKEAKEMIMSVLDTKSNRVTLKMDVSHTEHSHVIGKGGNNIKKVMEETGCHIHFPDSNRNNQAEKS NQVSIAGQPAGVESARVRIRELLPLVLMFELPIAGILQPVPDPNSPSIQHISQTYNISVSFKQRSRMYGATVIVRGSQNNTSAVKEGTAM LLEHLAGSLASAIPVSTQLDIAAQHHLFMMGRNGSNIKHIMQRTGAQIHFPDPSNPQKKSTVYLQGTIESVCLARQYLMGCLPLVLMFDM KEEIEVDPQFIAQLMEQLDVFISIKPKPKQPSKSVIVKSVERNALNMYEARKCLLGLESSGVTIATSPSPASCPAGLACPSLDILASAGL GLTGLGLLGPTTLSLNTSTTPNSLLNALNSSVSPLQSPSSGTPSPTLWAPPLANTSSATGFSAIPHLMIPSTAQATLTNILLSGVPTYGH TAPSPPPGLTPVDVHINSMQTEGKKISAALNGHAQSPDIKYGAISTSSLGEKVLSANHGDPSIQTSGSEQTSPKSSPTEGCNDAFVEVGM PRSPSHSGNAGDLKQMMCPSKVSCAKRQTVELLQGTKNSHLHSTDRLLSDPELSATESPLADKKAPGSERAAERAAAAQQNSERAHLAPR -------------------------------------------------------------- >In-frame_ENST00000263103_ENST00000369061_TCGA-W5-AA2W-01A_BICC1_chr10_60563002_+_FGFR2_chr10_123239535_length(transcript)=2771nt_BP=1083nt GATCCACAATTCATTGCGCAGTTGATGGAACAGCTTGATGTCTTCATCAGTATTAAACCAAAGCCCAAACAGCCAAGCAAGTCTGTGATT GTGAAAAGTGTTGAGCGAAATGCCTTAAATATGTATGAAGCAAGGAAATGTCTCCTCGGACTTGAAAGCAGTGGGGTTACCATAGCAACC AGTCCATCCCCAGCATCCTGCCCTGCCGGCCTGGCATGTCCCAGCCTGGATATCTTAGCTTCAGCAGGCCTTGGACTCACTGGACTAGGT CTTTTGGGACCCACCACCTTATCTCTGAACACTTCAACAACCCCAAACTCACTCTTGAATGCTCTTAATAGCTCAGTCAGTCCTTTGCAA AGTCCAAGTTCTGGTACACCCAGCCCCACATTATGGGCACCCCCACTTGCTAATACTTCAAGTGCCACAGGTTTTTCTGCTATACCACAC CTTATGATTCCATCTACTGCCCAAGCCACATTAACTAATATTTTGTTGTCTGGAGTGCCCACCTATGGGCACACAGCTCCATCTCCCCCT CCTGGCTTGACTCCTGTTGATGTCCATATCAACAGTATGCAGACCGAAGGCAAAAAAATCTCTGCTGCTTTAAATGGACATGCACAGTCT CCAGATATAAAATATGGTGCAATATCCACTTCATCACTTGGAGAAAAAGTGCTGAGTGCAAATCACGGGGATCCGTCCATCCAGACAAGT GGGTCTGAGCAGACATCTCCCAAATCAAGCCCCACTGAAGGTTGTAATGATGCTTTTGTTGAAGTAGGCATGCCTCGAAGTCCTTCCCAT TCTGGGAATGCTGGTGACTTGAAACAGATGATGTGTCCCTCCAAGGTTTCCTGTGCCAAAAGGCAGACAGTGGAACTATTGCAAGGCACG AAAAACTCACACTTACACAGCACTGACAGGTTGCTCTCAGACCCTGAACTGAGTGCTACCGAAAGCCCTTTGGCTGACAAGAAGGCTCCA GGGAGTGAGCGCGCTGCAGAGAGGGCAGCAGCTGCCCAGCAAAACTCCGAAAGGGCCCACCTTGCTCCACGGTCATCATATGTCAACATG CAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCACCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCT GTTTTTTCTCCAGACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAAACATGAATGACTGTGTCT GCCTGTCCCCAAACAGGACAGCACTGGGAACCTAGCTACACTGAGCAGGGAGACCATGCCTCCCAGAGCTTGTTGTCTCCACTTGTATAT ATGGATCAGAGGAGTAAATAATTGGAAAAGTAATCAGCATATGTGTAAAGATTTATACAGTTGAAAACTTGTAATCTTCCCCAGGAGGAG AAGAAGGTTTCTGGAGCAGTGGACTGCCACAAGCCACCATGTAACCCCTCTCACCTGCCGTGCGTACTGGCTGTGGACCAGTAGGACTCA AGGTGGACGTGCGTTCTGCCTTCCTTGTTAATTTTGTAATAATTGGAGAAGATTTATGTCAGCACACACTTACAGAGCACAAATGCAGTA TATAGGTGCTGGATGTATGTAAATATATTCAAATTATGTATAAATATATATTATATATTTACAAGGAGTTATTTTTTGTATTGATTTTAA ATGGATGTCCCAATGCACCTAGAAAATTGGTCTCTCTTTTTTTAATAGCTATTTGCTAAATGCTGTTCTTACACATAATTTCTTAATTTT CACCGAGCAGAGGTGGAAAAATACTTTTGCTTTCAGGGAAAATGGTATAACGTTAATTTATTAATAAATTGGTAATATACAAAACAATTA ATCATTTATAGTTTTTTTTGTAATTTAAGTGGCATTTCTATGCAGGCAGCACAGCAGACTAGTTAATCTATTGCTTGGACTTAACTAGTT ATCAGATCCTTTGAAAAGAGAATATTTACAATATATGACTAATTTGGGGAAAATGAAGTTTTGATTTATTTGTGTTTAAATGCTGCTGTC AGACGATTGTTCTTAGACCTCCTAAATGCCCCATATTAAAAGAACTCATTCATAGGAAGGTGTTTCATTTTGGTGTGCAACCCTGTCATT ACGTCAACGCAACGTCTAACTGGACTTCCCAAGATAAATGGTACCAGCGTCCTCTTAAAAGATGCCTTAATCCATTCCTTGAGGACAGAC CTTAGTTGAAATGATAGCAGAATGTGCTTCTCTCTGGCAGCTGGCCTTCTGCTTCTGAGTTGCACATTAATCAGATTAGCCTGTATTCTC TTCAGTGAATTTTGATAATGGCTTCCAGACTCTTTGGCGTTGGAGACGCCTGTTAGGATCTTCAAGTCCCATCATAGAAAATTGAAACAC AGAGTTGTTCTGCTGATAGTTTTGGGGATACGTCCATCTTTTTAAGGGATTGCTTTCATCTAATTCTGGCAGGACCTCACCAAAAGATCC AGCCTCATACCTACATCAGACAAAATATCGCCGTTGTTCCTTCTGTACTAAAGTATTGTGTTTTGCTTTGGAAACACCCACTCACTTTGC AATAGCCGTGCAAGATGAATGCAGATTACACTGATCTTATGTGTTACAAAATTGGAGAAAGTATTTAATAAAACCTGTTAATTTTTATAC >In-frame_ENST00000263103_ENST00000369061_TCGA-W5-AA2W-01A_BICC1_chr10_60563002_+_FGFR2_chr10_123239535_length(amino acids)=408AA_start in transcript=21_stop in transcript=1247 MMEQLDVFISIKPKPKQPSKSVIVKSVERNALNMYEARKCLLGLESSGVTIATSPSPASCPAGLACPSLDILASAGLGLTGLGLLGPTTL SLNTSTTPNSLLNALNSSVSPLQSPSSGTPSPTLWAPPLANTSSATGFSAIPHLMIPSTAQATLTNILLSGVPTYGHTAPSPPPGLTPVD VHINSMQTEGKKISAALNGHAQSPDIKYGAISTSSLGEKVLSANHGDPSIQTSGSEQTSPKSSPTEGCNDAFVEVGMPRSPSHSGNAGDL KQMMCPSKVSCAKRQTVELLQGTKNSHLHSTDRLLSDPELSATESPLADKKAPGSERAAERAAAAQQNSERAHLAPRSSYVNMQEYLDLS -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for BICC1-FGFR2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for BICC1-FGFR2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Top |
Related Diseases for BICC1-FGFR2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | BICC1 | C0011570 | Mental Depression | 2 | PSYGENET |
Hgene | BICC1 | C0011581 | Depressive disorder | 2 | PSYGENET |
Hgene | BICC1 | C0085413 | Polycystic Kidney, Autosomal Dominant | 1 | ORPHANET |
Hgene | BICC1 | C3275898 | RENAL DYSPLASIA, CYSTIC, SUSCEPTIBILITY TO | 1 | GENOMICS_ENGLAND;UNIPROT |
Tgene | FGFR2 | C2931196 | Craniofacial dysostosis type 1 | 23 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | FGFR2 | C0220658 | Pfeiffer Syndrome | 21 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | FGFR2 | C0001193 | Apert syndrome | 19 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C0795998 | JACKSON-WEISS SYNDROME | 10 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C0175699 | Saethre-Chotzen Syndrome | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
Tgene | FGFR2 | C1852406 | Cutis Gyrata Syndrome of Beare And Stevenson | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C2936791 | Antley-Bixler Syndrome, Autosomal Dominant | 7 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C1510455 | Acrocephalosyndactylia | 6 | CTD_human;ORPHANET |
Tgene | FGFR2 | C0265269 | Lacrimoauriculodentodigital syndrome | 5 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C0010278 | Craniosynostosis | 4 | CTD_human;GENOMICS_ENGLAND |
Tgene | FGFR2 | C1863389 | Apert-Crouzon Disease | 4 | CTD_human |
Tgene | FGFR2 | C1865070 | SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION | 4 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C0006142 | Malignant neoplasm of breast | 3 | CTD_human;UNIPROT |
Tgene | FGFR2 | C0030044 | Acrocephaly | 3 | CTD_human |
Tgene | FGFR2 | C0036341 | Schizophrenia | 3 | PSYGENET |
Tgene | FGFR2 | C0221356 | Brachycephaly | 3 | CTD_human |
Tgene | FGFR2 | C0265534 | Scaphycephaly | 3 | CTD_human |
Tgene | FGFR2 | C0265535 | Trigonocephaly | 3 | CTD_human |
Tgene | FGFR2 | C0376634 | Craniofacial Abnormalities | 3 | CTD_human |
Tgene | FGFR2 | C0678222 | Breast Carcinoma | 3 | CTD_human |
Tgene | FGFR2 | C1257931 | Mammary Neoplasms, Human | 3 | CTD_human |
Tgene | FGFR2 | C1458155 | Mammary Neoplasms | 3 | CTD_human |
Tgene | FGFR2 | C1833340 | Synostotic Posterior Plagiocephaly | 3 | CTD_human |
Tgene | FGFR2 | C1860819 | Metopic synostosis | 3 | CTD_human |
Tgene | FGFR2 | C2931150 | Synostotic Anterior Plagiocephaly | 3 | CTD_human |
Tgene | FGFR2 | C3281247 | BENT BONE DYSPLASIA SYNDROME | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | FGFR2 | C4551902 | Craniosynostosis, Type 1 | 3 | CTD_human |
Tgene | FGFR2 | C4704874 | Mammary Carcinoma, Human | 3 | CTD_human |
Tgene | FGFR2 | C0008925 | Cleft Palate | 2 | CTD_human |
Tgene | FGFR2 | C0011570 | Mental Depression | 2 | PSYGENET |
Tgene | FGFR2 | C0011581 | Depressive disorder | 2 | PSYGENET |
Tgene | FGFR2 | C0024623 | Malignant neoplasm of stomach | 2 | CGI;CTD_human |
Tgene | FGFR2 | C0038356 | Stomach Neoplasms | 2 | CGI;CTD_human |
Tgene | FGFR2 | C1708349 | Hereditary Diffuse Gastric Cancer | 2 | CTD_human |
Tgene | FGFR2 | C1837218 | Cleft palate, isolated | 2 | CTD_human |
Tgene | FGFR2 | C0000772 | Multiple congenital anomalies | 1 | CTD_human |
Tgene | FGFR2 | C0003090 | Ankylosis | 1 | CTD_human |
Tgene | FGFR2 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
Tgene | FGFR2 | C0008924 | Cleft upper lip | 1 | CTD_human |
Tgene | FGFR2 | C0010273 | Craniofacial Dysostosis | 1 | CTD_human |
Tgene | FGFR2 | C0011757 | Developmental Coordination Disorder | 1 | CTD_human |
Tgene | FGFR2 | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
Tgene | FGFR2 | C0018553 | Hamartoma Syndrome, Multiple | 1 | CTD_human |
Tgene | FGFR2 | C0020796 | Profound Mental Retardation | 1 | CTD_human |
Tgene | FGFR2 | C0023890 | Liver Cirrhosis | 1 | CTD_human |
Tgene | FGFR2 | C0024121 | Lung Neoplasms | 1 | CTD_human |
Tgene | FGFR2 | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human |
Tgene | FGFR2 | C0026613 | Motor Skills Disorders | 1 | CTD_human |
Tgene | FGFR2 | C0033975 | Psychotic Disorders | 1 | PSYGENET |
Tgene | FGFR2 | C0037268 | Skin Abnormalities | 1 | CTD_human |
Tgene | FGFR2 | C0037274 | Dermatologic disorders | 1 | CTD_human |
Tgene | FGFR2 | C0038219 | Status Dysraphicus | 1 | CTD_human |
Tgene | FGFR2 | C0040427 | Tooth Abnormalities | 1 | CTD_human |
Tgene | FGFR2 | C0080178 | Spina Bifida | 1 | CTD_human |
Tgene | FGFR2 | C0152423 | Congenital small ears | 1 | GENOMICS_ENGLAND |
Tgene | FGFR2 | C0206698 | Cholangiocarcinoma | 1 | CTD_human |
Tgene | FGFR2 | C0206762 | Limb Deformities, Congenital | 1 | CTD_human |
Tgene | FGFR2 | C0239946 | Fibrosis, Liver | 1 | CTD_human |
Tgene | FGFR2 | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
Tgene | FGFR2 | C0265326 | Bannayan-Riley-Ruvalcaba Syndrome | 1 | CTD_human |
Tgene | FGFR2 | C0266508 | Rachischisis | 1 | CTD_human |
Tgene | FGFR2 | C0345905 | Intrahepatic Cholangiocarcinoma | 1 | CTD_human |
Tgene | FGFR2 | C0349204 | Nonorganic psychosis | 1 | PSYGENET |
Tgene | FGFR2 | C0391826 | Lhermitte-Duclos disease | 1 | CTD_human |
Tgene | FGFR2 | C0476089 | Endometrial Carcinoma | 1 | CGI;CTD_human |
Tgene | FGFR2 | C0524730 | Odontome | 1 | CTD_human |
Tgene | FGFR2 | C0699791 | Stomach Carcinoma | 1 | CGI;GENOMICS_ENGLAND |
Tgene | FGFR2 | C0917816 | Mental deficiency | 1 | CTD_human |
Tgene | FGFR2 | C1450010 | Plagiocephaly, Nonsynostotic | 1 | CTD_human |
Tgene | FGFR2 | C1860042 | Antley-Bixler Syndrome with Disordered Steroidogenesis | 1 | CTD_human |
Tgene | FGFR2 | C1867564 | SCAPHOCEPHALY AND AXENFELD-RIEGER ANOMALY | 1 | GENOMICS_ENGLAND |
Tgene | FGFR2 | C1959582 | PTEN Hamartoma Tumor Syndrome | 1 | CTD_human |
Tgene | FGFR2 | C2350233 | Antley-Bixler Syndrome Phenotype | 1 | CTD_human |
Tgene | FGFR2 | C3267076 | Familial scaphocephaly syndrome | 1 | GENOMICS_ENGLAND |
Tgene | FGFR2 | C3714756 | Intellectual Disability | 1 | CTD_human |
Tgene | FGFR2 | C3805278 | Extrahepatic Cholangiocarcinoma | 1 | CTD_human |